Boehringer's COPD spray Combivent Respimat gets FDA approval

10/9/2011 | Family Practice News · Medscape (free registration)

The FDA approved Combivent Respimat Inhalation Spray, Boehringer Ingelheim's treatment for patients with chronic obstructive pulmonary disease. The therapy comprises albuterol sulfate and ipratropium bromide. It is a "suitable alternative" to chlorofluorocarbon-based Combivent inhalation aerosol, which will be phased out after Dec. 31, 2013, according to an FDA statement.

View Full Article in:

Family Practice News · Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD